Investor Relations

Latest News

Jul 28, 2021

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

View Press Release

Jul 15, 2021

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

Jun 29, 2021

DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD

View All News

DiaMedica Corporate Presentation

View Presentation

Aug 9 – Aug 10, 2021

BTIG Virtual Biotechnology Conference 2021

View All

Sep 13 – Sep 15, 2021

H.C. Wainwright 23rd Annual Global Investment Conference

View All

Sep 14 – Sep 15, 2021

Lake Street BIG5 Conference

View All

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

View Board of Directors

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447